Novavax, Inc (NASDAQ:NVAX) price on current trading day, rose 2.09% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $7.32.
A look at the stock’s price movement, the close in the last trading session was $7.17. Turning to its 52-week performance, $23.86 and $3.81 were the 52-week high and 52-week low respectively. Overall, NVAX moved -21.46% over the past month.
Novavax, Inc’s market cap currently stands at around $1.17 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 84.38M for the company’s revenue for the quarter, with a low and high estimate of 80M and 88.8M respectively. The average forecast suggests down to a -71.04% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 684.95M, representing a -30.37% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NVAX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
16 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 6 analyst(s) rate the stock as a Hold, 10 recommend NVAX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NVAX’s current price about -10.14% and -14.87% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 35.36, while 7-day volatility ratio is 6.87% and 5.65% in the 30-day chart. Further, Novavax, Inc (NVAX) has a beta value of 2.93, and an average true range (ATR) of 0.50. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $14 and high of $25. Looking at the price targets, the low is -91.26% off current price level while to achieve the yearly target high, price needs to move -241.53%. Nonetheless, investors will most likely welcome a -200.55% jump to $22 which is the analysts’ median price.
If we refocus on Novavax, Inc (NASDAQ:NVAX), historical trading data shows that trading volumes averaged 3.99 million over the past 3 months. The company’s latest data on shares outstanding shows there are 160.15 million shares.
The 8.77% of Novavax, Inc’s shares are in the hands of company insiders while institutional holders own 60.07% of the company’s shares. Current price change has pushed the stock -8.96% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NVAX stock continues to rise going into the next quarter.
